Off-label GLP-1 medication use surges among children under 12 for obesity treatment

Despite lacking formal FDA approval for this age group, prescriptions for GLP-1 receptor agonists in children under 12 have skyrocketed, driven by rising childhood obesity rates and associated long-term health risks.